Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.
7
Supplemental Figure 1
-
Upload
jarod-yelvington -
Category
Documents
-
view
246 -
download
7
Transcript of Supplemental Figure 1. Supplemental Figure 2 Supplemental Figure 3 A B.
Supplemental Figure 1
Supplemental Figure 2
Supplemental Figure 3
AB
OCI-AML3
IgG Control Control 250 1000 nM SP2509, 24 h
CD86 CD86 CD86
MOLM13
CD86 CD86 CD86
Supplemental Figure 4
A
B
MV4-11 SP2509 + PS combination indices
SP2509 PS Fa CI(nM) (nM)500 2.5 0.463 0.541600 3 0.555 0.452750 3.75 0.618 0.438800 4 0.607 0.489900 4.5 0.63 0.5001000 5 0.705 0.399
MV4-11SP2509 + PS
0 0.2 0.4 0.6 0.8 1.00
0.5
1.0
1.5
Fractional Effect
CI
C
Supplemental Figure 5
OCI-AML3 SP2509 + PS combination indices
SP2509 PS Fa CI(nM) (nM)500 5 0.294 0.927600 6 0.486 0.757750 7.5 0.668 0.666800 8 0.659 0.724900 9 0.723 0.7081000 10 0.762 0.716
MOLM13 SP2509 + PS combination indices
SP2509 PS Fa CI(nM) (nM)500 5 0.396 0.759600 6 0.467 0.671750 7.5 0.434 0.963800 8 0.584 0.565900 9 0.564 0.6871000 10 0.624 0.605
A B
Primary CD34+ CD38- Lin- AML combination indices
SP2509 (nM)
PS (nM)
Fa CI
225 10 0.404 0.719
250 10 0.581 0.407
500 10 0.57 0.458
600 10 0.58 0.449
750 10 0.598 0.428
1000 10 0.635 0.379
D
B
*
OCI-AML3
p21
p16
EZH2
C/EBPα p42
C/EBPα p30
LSD1
SUZ12
β-Actin
250 nM SP2509, 96 h
5 nM PS, 96 h- - + +
- + - +A
Supplemental Figure 6
Supplemental Figure 7
Primary AMLSP2509 and PS
SP2509(nM)
PS(nM)
Effect CI
250.0 10.0 0.466 0.19902
500.0 10.0 0.541 0.10616
600.0 10.0 0.540 0.11361
750.0 10.0 0.567 0.09734
900.0 10.0 0.573 0.10096
1000.0 10.0 0.608 0.07777
A B
